Thalassemia affected children treated under Tamil Nadu CMCHIS by Apollo Cancer Centre
Bone marrow transplantation is the only curative option for Thalassemia major, Aplastic Anemia, and Primary Immune Deficiencies.
Source: thenewsminute.com
📰 Primary Immune News
Primary Immune News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Primary Immune. Real-time updates on events, politics, business and more.
Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo ; responders observed across patient types regardless of prior... | May 5, 2022
Source: marketscreener.com
AstraZeneca, Argenx Score Phase III Wins in Autoimmune Space
Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.
Seanj Pittock Argenx Vyvgart Astrazeneca Ultomiris Catherine Broome Mayo Neuroimmunology Laboratory Drug Administration
Source: biospace.com
NewsNow: Cancer Research news | Breaking News & Search 24/7
Breaking news headlines about Cancer Research, linking to 1,000s of sources around the world, on NewsNow: the one-stop shop for breaking news
Source: newsnow.co.uk